Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-18

Clinical Trial Update: Sublingual Fentanyl for the Management of Breakthrough Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of sublingual fentanyl for breakthrough pain in advanced cancers was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • sublingual fentanyl (fentanyl)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancers | Phase 2 | Status: TERMINATED | Results posted: 2021-05-18